Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217540 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025. Verfasst von Xiaowen Cui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Molecular Targeted Therapy, Biomarkers, Tumor. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 152 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is a serious public health issue due to its insidious onset and dismal prognosis. The past few years have witnessed and highlighted the development of understanding and management of CCA. The combination of gemcitabine and cisplatin (GP) chemotherapy regimen with immunotherapy using immune checkpoint inhibitors has been considered the new standard first-line treatment alternative for advanced CCA. Notably, the proportion of patients with advanced CCA with targetable genetic mutations is approximately 40 %, and these patients may be considered for molecularly targeted therapy in the second-line treatment. In this review, we highlight the advances and progress in targeted therapies for advanced CCA, with special attention to data from Asian populations, including Chinese. In addition, we present in detail the phosphatase tension homolog (PTEN), a novel biomarker for both of first-line chemotherapy and second-line targeted therapy in advanced CCA, and its ability to forecast prognosis in patients with CCA. The mechanisms of rapid resistance to targeted agents warrant further investigation and address in light of the development of new targeted therapies. Precision medicine is gradually playing an increasing role in achieving optimal therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, Shanghai, China.
- International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, The Naval Medical University, Shanghai, China; Institute of Metabolism and Integrative Biology, Fudan University, Shanghai,…
- International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, The Naval Medical University, Shanghai, China. Electronic address: jiangtianyi@smmu.edu.cn.
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, Shanghai, China; International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, The Naval Med…
Förderung
- National Key Research and Development Program of China
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Cui, X., Huang, T., Jiang, T., & Wang, H. (2025). Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217540
Vancouver
Cui X, Huang T, Jiang T, Wang H. Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217540
BibTeX
@article{Cui2025,
author = {Cui, Xiaowen and Huang, Teng and Jiang, Tianyi and Wang, Hongyang},
title = {Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217540}
}
EUVIMED